MicroRNA-520b Suppresses Proliferation, Migration, and Invasion of Spinal Osteosarcoma Cells Via Downregulation of Frizzled-8

Overview

Journal Oncol Res

Specialty Oncology

Date 2017 Mar 2

PMID 28247840

Citations 19

Authors

Jin Wang

Wenquan Pang

Zhenbai Zuo

Wenyan Zhang

Weidong He

Affiliations

Soon will be listed here.

Abstract

Spinal osteosarcoma (OS) is a malignant tumor that has a poor outcome. MicroRNA-520b (miR-520b) acts as a cancer suppressor in various types of cancer. Because of the limited amount of literature on OS, we aimed to identify the role of miR-520b in OS. The miR-520b level in clinical spinal OS tissues and adjacent nontumor tissues as well as in cell lines was assessed. The effect of miR-520b on cell proliferation, migration, invasion, and frizzled-8 (FZD8) degradation were all evaluated. Alterations of key proteins involved in the Wnt/β-catenin pathway were assessed by Western blot analysis. In the present study, miR-520b was downregulated in human spinal OS tissues and OS cell lines (p < 0.01 or p < 0.001). Overexpression of miR-520b inhibited cell proliferation (p < 0.01 or p < 0.001), migration (p < 0.01), and invasion (p < 0.01). FZD8 expression was negatively regulated by infection with a lentivirus vector carrying an miR-520b precursor in dose- and time-dependent manners. In OS tissues, miR-520b was inversely correlated with FZD8 expression. FZD8 was upregulated in human spinal OS tissues and cell lines. Finally, miR-520b inactivated the Wnt/β-catenin pathway through downregulation of FZD8. miR-520b inhibited cell proliferation, migration, and invasion through inactivating the Wnt/β-catenin pathway by downregulation of FZD8, providing a novel therapeutic target for spinal OS.

Citing Articles

Expression pattern, prognostic value and potential microRNA silencing of FZD8 in breast cancer.

Al-Zahrani M, Assidi M, Pushparaj P, Al-Maghrabi J, Zari A, Abusanad A Oncol Lett. 2023; 26(5):477.

PMID: 37809047 PMC: 10551865. DOI: 10.3892/ol.2023.14065.

LncRNA ZFAS1 contributes to osteosarcoma progression via miR-520b and miR-520e-mediated inhibition of RHOC signaling.

Liu X, Wang M, Zhang L, Huang L Clinics (Sao Paulo). 2022; 78:100143.

PMID: 36473367 PMC: 9727593. DOI: 10.1016/j.clinsp.2022.100143.

Modulation of immunosuppressive cells and noncoding RNAs as immunotherapy in osteosarcoma.

Xia Y, Wang D, Piao Y, Chen M, Wang D, Jiang Z Front Immunol. 2022; 13:1025532.

PMID: 36457998 PMC: 9705758. DOI: 10.3389/fimmu.2022.1025532.

Non-Coding RNA and Frizzled Receptors in Cancer.

Smith A, Sompel K, Elango A, Tennis M Front Mol Biosci. 2021; 8:712546.

PMID: 34671643 PMC: 8521042. DOI: 10.3389/fmolb.2021.712546.

FGF16 regulated by miR-520b enhances the cell proliferation of lung cancer.

He W, Liu X, Luo Z, Li L, Fang X Open Med (Wars). 2021; 16(1):419-427.

PMID: 33758783 PMC: 7961213. DOI: 10.1515/med-2021-0232.

References

Jamieson C, Sharma M, Henderson B . Targeting the β-catenin nuclear transport pathway in cancer. Semin Cancer Biol. 2014; 27:20-9. DOI: 10.1016/j.semcancer.2014.04.012. View

Sampson E, Martin B, Morris A, Xie C, Schwarz E, OKeefe R . The orally bioavailable met inhibitor PF-2341066 inhibits osteosarcoma growth and osteolysis/matrix production in a xenograft model. J Bone Miner Res. 2011; 26(6):1283-94. DOI: 10.1002/jbmr.336. View

Shafiee M, Aleyasin S, Vasei M, Semnani S, Mowla S . Down-Regulatory Effects of miR-211 on Long Non-Coding RNA SOX2OT and SOX2 Genes in Esophageal Squamous Cell Carcinoma. Cell J. 2016; 17(4):593-600. PMC: 4746409. DOI: 10.22074/cellj.2016.3811. View

Zhang P, Yang Y, Zweidler-McKay P, Hughes D . Retraction: Critical role of notch signaling in osteosarcoma invasion and metastasis. Clin Cancer Res. 2013; 19(18):5256-7. PMC: 4375543. DOI: 10.1158/1078-0432.CCR-13-1914. View

Zhang W, Lu Z, Gao Y, Ye L, Song T, Zhang X . MiR-520b suppresses proliferation of hepatoma cells through targeting ten-eleven translocation 1 (TET1) mRNA. Biochem Biophys Res Commun. 2015; 460(3):793-8. DOI: 10.1016/j.bbrc.2015.03.108. View

Xu N, Li Z, Yu Z, Yan F, Liu Y, Lu X . MicroRNA-33b suppresses migration and invasion by targeting c-Myc in osteosarcoma cells. PLoS One. 2014; 9(12):e115300. PMC: 4278906. DOI: 10.1371/journal.pone.0115300. View

Lu T, Zhang C, Chai M, An Y, Jia J . MiR-374a promotes the proliferation of osteosarcoma cell proliferation by targeting Axin2. Int J Clin Exp Pathol. 2015; 8(9):10776-83. PMC: 4637604. View

Mutsaers A, Walkley C . Cells of origin in osteosarcoma: mesenchymal stem cells or osteoblast committed cells?. Bone. 2014; 62:56-63. DOI: 10.1016/j.bone.2014.02.003. View

Isakoff M, Bielack S, Meltzer P, Gorlick R . Osteosarcoma: Current Treatment and a Collaborative Pathway to Success. J Clin Oncol. 2015; 33(27):3029-35. PMC: 4979196. DOI: 10.1200/JCO.2014.59.4895. View

10.

Martin S, Dwyer A, KISSANE J, Costa J . Small-cell osteosarcoma. Cancer. 1982; 50(5):990-6. DOI: 10.1002/1097-0142(19820901)50:5<990::aid-cncr2820500529>3.0.co;2-r. View

11.

Niu G, Li B, Sun J, Sun L . miR-454 is down-regulated in osteosarcomas and suppresses cell proliferation and invasion by directly targeting c-Met. Cell Prolif. 2015; 48(3):348-55. PMC: 6496886. DOI: 10.1111/cpr.12187. View

12.

DeAlmeida V, Miao L, Ernst J, Koeppen H, Polakis P, Rubinfeld B . The soluble wnt receptor Frizzled8CRD-hFc inhibits the growth of teratocarcinomas in vivo. Cancer Res. 2007; 67(11):5371-9. DOI: 10.1158/0008-5472.CAN-07-0266. View

13.

Mathkour M, Garces J, Beard B, Bartholomew A, Sulaiman O, Ware M . Primary High-Grade Osteosarcoma of the Clivus: A Case Report and Literature Review. World Neurosurg. 2016; 89:730.e9-730.e13. DOI: 10.1016/j.wneu.2016.01.054. View

14.

Li S, Zhang H, Ning T, Wang X, Liu R, Yang H . MiR-520b/e Regulates Proliferation and Migration by Simultaneously Targeting EGFR in Gastric Cancer. Cell Physiol Biochem. 2016; 40(6):1303-1315. DOI: 10.1159/000453183. View

15.

Klaus A, Birchmeier W . Wnt signalling and its impact on development and cancer. Nat Rev Cancer. 2008; 8(5):387-98. DOI: 10.1038/nrc2389. View

16.

Ashihara E, Takada T, Maekawa T . Targeting the canonical Wnt/β-catenin pathway in hematological malignancies. Cancer Sci. 2015; 106(6):665-671. PMC: 4471797. DOI: 10.1111/cas.12655. View

17.

Wei R, Deng Z, Su J . miR-217 targeting Wnt5a in osteosarcoma functions as a potential tumor suppressor. Biomed Pharmacother. 2015; 72:158-64. DOI: 10.1016/j.biopha.2015.04.012. View

18.

Katonis P, Datsis G, Karantanas A, Kampouroglou A, Lianoudakis S, Licoudis S . Spinal osteosarcoma. Clin Med Insights Oncol. 2013; 7:199-208. PMC: 3813616. DOI: 10.4137/CMO.S10099. View

19.

Yin S, Xu L, Bonfil R, Banerjee S, Sarkar F, Sethi S . Tumor-initiating cells and FZD8 play a major role in drug resistance in triple-negative breast cancer. Mol Cancer Ther. 2013; 12(4):491-8. PMC: 3624033. DOI: 10.1158/1535-7163.MCT-12-1090. View

20.

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View